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ABSTRACT
Background Options for patients with ventricular 
tachycardia (VT) refractory to antiarrhythmic drugs and/or 
catheter ablation remain limited. Stereotactic radiotherapy 
has been described as a novel treatment option.
Methods Seven patients with recurrent refractory VT, 
deemed high risk for either first time or redo invasive 
catheter ablation, were treated across three UK 
centres with non- invasive cardiac stereotactic ablative 
radiotherapy (SABR). Prior catheter ablation data and non- 
invasive mapping were combined with cross- sectional 
imaging to generate radiotherapy plans with aim to deliver 
a single 25 Gy treatment. Shared planning and treatment 
guidelines and prospective peer review were used.
Results Acute suppression of VT was seen in all seven 
patients. For five patients with at least 6 months follow- 
up, overall reduction in VT burden was 85%. No high- 
grade radiotherapy treatment- related side effects were 
documented. Three deaths (two early, one late) occurred 
due to heart failure.
Conclusions Cardiac SABR showed reasonable VT 
suppression in a high- risk population where conventional 
treatment had failed.
INTRODUCTION
Structural heart disease and impaired 
ventricular function increase the risk of life- 
threatening arrhythmia including ventricular 
tachycardia (VT). Current approaches to the 
management of VT involve the placement 
of implantable cardioverter defibrillators 
(ICDs), use of antiarrhythmic drugs (AADs) 
and/or catheter ablation.1 Although ICDs 
improve patient survival, ICD shocks can be 
detrimental to quality of life and are associ-
ated with poor prognosis.2 AADs have modest 
efficacy and can have significant side effects.3 
Catheter ablation is effective for control of VT 
and reduction in ICD shocks, but also repre-
sents a prolonged, technically challenging 
procedure that may pose higher risks to more 
frail patients.4 5
Stereotactic radiotherapy (SABR) is a tech-
nique for treating targets anywhere in the 
body, made possible by advances in radiation 
treatment planning, imaging guidance and 
delivery systems. High doses of radiation can 
be precisely delivered to defined targets, with 
a steep drop off in dose gradients to minimise 
dose to surrounding normal tissues. SABR 
achieves very high local tumour control rates 
with low toxicity and has been widely adopted 
in the management of a range of cancers, 
including lung, prostate, liver, kidney 
and pancreas.6 Following the first patient 
Key questions
What is already known about this subject?
 ► Patients with uncontrolled ventricular arrhythmias 
related to cardiac scar tend to have a poor progno-
sis and significant morbidity. This is related to both 
frequent arrythmia episodes and treatment thereof, 
as well as their underlying cardiac dysfunction.
 ► Stereotactic radiotherapy (SABR) is an established 
treatment for many cancers.
What does this study add?
 ► We report initial UK experience with cardiac SABR 
treatment of refractory ventricular arrhythmias.
 ► Across three centres, a multidisciplinary approach 
with collaboration between cardiology (electrophys-
iology and imaging) and oncology teams (clinical 
oncology and medical physics) was employed to 
successfully deliver treatment.
How might this impact on clinical practice?
 ► This represents an exciting and novel non- invasive 
treatment option, but further clinical trials, refine-
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treatment in 2012,7 several single centre case series8 9 
and a Phase I/II study (EP- guided Noninvasive Cardiac 
Radioablation for treatment of Ventricular Tachycardia 
(ENCORE- VT))10 have demonstrated the potential for 
non- invasive cardiac SABR treatment to control VT where 
conventional treatment has failed. However, to date the 
entire literature describes less than 60 patients treated by 
this novel approach.11–13 Recognising the urgent need for 
more effective treatments in patients with refractory VT, 
three UK tertiary cardiac centres agreed to collaborate in 
developing cardiac SABR services aiming to maximise the 
benefits of combined experience of a novel technique. 
We now report our initial experiences.
METHODS
Each institution obtained formed a local cardiology 
and oncology working group and obtained institutional 
approval for use of the established SABR service in a 
novel compassionate use indication. Working with the 
ENCORE- VT trial group,10 planning, treatment and 
follow- up guidelines were developed and shared.
Over the period June 2019 to January 2020, seven 
patients with recurrent VT despite AAD use and prior 
invasive VT ablation or contra- indication to invasive VT 
ablation underwent cardiac SABR treatment. All patients 
received acute initial stabilisation measures including 
correction of electrolytes, optimisation of heart failure 
management and additional AADs where appropriate. 
All patients were discussed in cardiology and oncology 
meetings at each local centre, and also with the other 
two UK centres prior to proposing SABR treatment. All 
patients gave interdisciplinary informed consent and 
treatment was delivered on outpatient basis with option of 
overnight hospital admission post- treatment permitted at 
clinician discretion due to novelty of cardiac SABR treat-
ment. Patient characteristics are summarised in table 1.
Pre-treatment workup
Four- dimensional (4D) high- resolution cardiac and 
respiratory cycle (radiotherapy planning) CT scans were 
both performed with intravenous contrast (and oral 
contrast if deemed necessary to demonstrate gastrointes-
tinal tract for inferior wall targets) and co- registered. The 
cardiac CT scan was used to define cardiac structures in 
particular regions of scar based on myocardial wall thick-
ness, and the radiotherapy planning CT scan was used to 
define extracardiac structures. Cardiac MRI and nuclear 
medicine scans were also used to define myocardial scar 
where available.
Clinical 12 lead ECGs of VT and prior invasive electro-
physiology data, including electroanatomic voltage and 
activation maps, were reviewed by two electrophysiolo-
gists from each centre to agree on VT exit sites. In six of 
seven patients, inducibility of clinical VT and other VTs 
as tolerated was confirmed by a non- invasive electrophys-
iology study (programmed stimulation through ICD) 
combined with body surface mapping using the View into 
Ventricular Onset (VIVO system - Catheter Precision).
In general, the integration of structural and ECG data 
was performed manually by side to side comparison and 
clinician consensus. Use of the 17 segment cardiac model 
was encouraged to facilitate communication between 
physicians and centres. In Sheffield, an additional step 
was developed to fuse imaging data (DICOM format) and 
electroanatomic map (EAM)/VIVO data (.dif or .vtk) 
using Mimics Innovation Suite, V.23 (Materialise, Leuven, 
Belgium). Deformable registration techniques were used 
to fuse the various modalities using the CT as the primary 
fixed image for planning review. This permitted a three- 
dimensional target to be defined directly on the myocar-
dial surface and a target volume generated by extruding 
the surface through the myocardium. This volume was 
exported to directly generate a DICOM RT structure in 
Eclipse (n=2, Varian Medical Systems). For the two other 
Table 1 Demographics
Patient Age Gender LVEF Aetiology NYHA Device Antiarrhythmic drugs Prior catheter ablation
1 (STH) 70s M 20 Myocarditis III CRTD A 300 mg once a day
R 500 mg two times per day
(intolerant Me)
2
2 (NUTH) 70s F 30 Idiopathic IV CRTD A 200 mg once a day 3
3 (JCUH) 70s M 45 Ischaemic II ICD A 200 mg once a day 1
4 (NUTH) 60s M 35 Ischaemic II ICD A 200 mg once a day 3
5 (STH) 60s M 15 Ischaemic II CRTD Me 300 mg three times a day
(prior use of A, R)
2
6 (NUTH) 70s F 25 Ischaemic III ICD A 200 mg once a day
(prior use of Me, P)
2
7 (JCUH) 70s F 20 Ischaemic III CRTD A 200 mg once a day 0
A, amiodarone; CRTD, biventricular implantable defibrillator; F, female; ICD, implantable defibrillator; JCUH, James Cook University Hospital 
Middlesbrough; LVEF, left ventricular ejection fraction; M, male; Me, mexiletine; NUTH, Newcastle Hospitals NHS Foundation Trust; NYHA, 
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centres, segments of scar adjacent to VT exit site loca-
tion(s) were manually delineated for gross target volume 
(GTV) on the respiratory gated 4D radiotherapy plan-
ning scan using either Monaco (n=2, Middlesbrough, 
Elekta) or Raystation (n=3, Newcastle, RaySearch Labo-
ratories) software. Illustrative workflow for the image 
fusion approach to define the cardiac target is presented 
in figure 1 and a summary of target selection data is given 
in table 2.
Cardiac GTV margins were expanded to account for 
cardiac and respiratory motion to generate the internal 
target volume. Finally, a 3–5 mm margin was added to 
account for variation in patient positioning thus gener-
ating the final planning target volume (PTV). Treatment 
plans were produced with aim to achieve single dose 
25 Gy treatment to 95% of PTV—see example in figure 2. 
Dose constraints to off target structures such as thoracic 
and abdominal organs were based on the ENCORE- VT 
protocol and American Association of Physicists in Medi-
cine guidelines.14 15 Dose was also minimised to device 
lead tips and proximal coronary arteries. In two patients 
with inferior wall targets, the stomach was in close prox-
imity and at risk of exceeding pre- specified 17.4 Gy organ 
at risk limit. Two different approaches were used—in 
patient 1, the overall SABR dose was reduced to 20 Gy, 
while in patient 3, stomach plus 8 mm margin was removed 
from the PTV. Further detailed information on SABR 
plans is provided in the online supplemental data table 
1 as per International Commission on Radiation Units 
and Measurements (ICRU) 91 reporting standards.16 
Figure 1 Illustrative workflow—cardiac CT imaging is 
combined with electrophysiology mapping data into a single 
three- dimensional model used to define a target region for 
import into radiotherapy planning software.
Table 2 Targeting details
Patient Scar segments (MRI/CT)
Clinical VT
(12 lead ECG) VIVO NIPS—VT exit Segments targeted Treatment
1 (STH) 10, 11, 15,16 10, 15 Not performed 10, 15 Jun 2019
2 (NUTH) 5 (EAM) N/A* 1, 5, 6, 17 1, 5, 6, 17 Jun 2019
3 (JCUH) 3, 4, 9, 10 10 3, 4 3, 4, 10 Jul 2019
4 (NUTH) 4, 10, 15 4 10 4, 10 Dec 2019
5 (STH) 3, 4, 9, 10, 15 15 9, 10 9, 10, 15 Jan 2020
6 (NUTH) 13, 14, 16, 17 13, 17 14, 16 13, 14, 16, 17 Jan 2020
7 (JCUH) 2, 3, 4, 5, 8, 9, 10, 11, 14 N/A* 14 2, 3, 8, 9, 14 Jan 2020
*Device electrogram data available only.
EAM, electroanatomic map; JCUH, James Cook University Hospital Middlesbrough; NIPS, non invasive programmed stimulation; NUTH, 
Newcastle Hospitals NHS Foundation Trust; STH, Sheffield Teaching Hospitals; VIVO, view into ventricular onset (non- invasive mapping); VT, 
ventricular tachycardia.
Figure 2 Example cardiac SABR plan from patient 3—top 
panel ‘isodose’ areas show how 25 Gy SABR treatment is 
focused on cardiac target area, bottom panel—dose- volume 
histogram demonstrating how treatment to off- target organs 
at risk is minimised. CORS, coronary arteries; PTVoptim, 
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A remote peer- review process was set up between three 
UK centres and with Center for Non- invasive Cardiac 
Radioablation, Washington University, St Louis. Anony-
mised clinical data and treatment plans were uploaded to 
a secure server and online meetings were held to review 
case data.
Treatment delivery and follow-up
During treatment with the Linear Accelerator (Varian 
Medical Systems/Elekta), departmental patient immo-
bilisation techniques were used which included use of 
abdominal compression in cases where it was observed 
to help limit respiratory movement. A Day 0 ‘practice 
run’ was recommended to give experience with indi-
vidual patient positioning and cone beam CT registra-
tion. Matching was performed on bony structures, device 
leads and left ventricle outline. Treatment used intensity- 
modulated planning and delivery. Single fraction high- 
dose treatment was delivered during free breathing 
without any cardiac fiducial marker gating. See table 3 for 
summary of treatment delivery. Overnight hospital admis-
sion was left at clinician discretion. Most patients had an 
indication for oral anticoagulation (usually atrial fibrilla-
tion), but if not anticoagulation for 4 weeks post SABR 
was recommended. Patients were then followed with a 
combination of telephone and in person appointments 
at 6 weeks and then every 3 months, and through the 
remote monitoring function of their ICDs. Transthoracic 
echo was undertaken at 6 weeks, no routine follow- up CT 
imaging was undertaken. Following the first 6 weeks after 
SABR, clinicans were encouraged to reduce antiarrhyth-
mics if possible. Patient ICD settings including monitor 
zones were programmed at the discretion of the local 
centre, with the common aim of maximising VT detec-
tion. During follow- up, all device detected VT episodes 
were reviewed by an electrophysiologist to confirm the 
diagnosis.
RESULTS
Acute observations—first 60 days
All patients were successfully treated—see table 3 for 
specific details of target volume and treatment time. In 
patient 2, acute termination and suppression of sustained 
VT was observed during SABR treatment. Troponin 
measurement taken 24 hours post SABR in two patients 
remained in normal range in patient 1 and showed an 
insignificant rise to less than two times upper limit normal 
in patient 5. Observed radiotherapy toxicity was limited 
to Common Terminology Criteria for Adverse Events 
(CTCAE) Grade 1 fatigue in two patients and no toxicity 
in terms of lung, cardiac, GI side- effects was observed 
clinically. No change in LV function was seen on echo 
at 6 weeks. Patient 1 had an acute flare up of VT post 
SABR that required temporary escalation of amiodarone 
and ranolazine doses for 2 months. Patient 3 also experi-
enced further VT post SABR with a different inferior exit 
site that required escalation of AADs and then underwent 
repeat catheter ablation 7 weeks after SABR. No signif-
icant changes were noted in the bipolar endocardial 
voltage map to reflect recent SABR treatment.
Despite acute reduction of VT episodes, patient 2 and 
patient 7 both died of progressive heart failure within 
4 weeks of treatment. Patient 2 was challenging to treat 
due to lack of anatomic scar on CT/MRI and multiple VT 
exit sites documented clinically and at VIVO non inva-
sive programmed stimulation (NIPS) involving anterior, 
posterolateral, summit and apex regions of LV. Both of 
these patients were either New York Heart Association 
(NYHA) class IV status at the time of treatment or deterio-
rated to class IV shortly afterwards. Postmortem histology 
was obtained in patient 7 with kind permission from 
patient’s family. No acute radiotherapy changes were 
detected in surrounding organs, though acute changes 
in the heart were observed—see figure 3. Myocardium in 
the vicinity of the treated area showed established fibrosis 
from prior ischaemic damage. Non- fibrotic myocardium 
showed an increase in capillary vascularity as might be 
expected in relation to radiation treatment. No other 
histologic features of radiation exposure such as acute 
necrosis, changes in blood vessel wall, thrombosis, fibro-
blast proliferation or nuclear atypia were seen.
VT burden and survival
Of the remaining five patients, patient 1 died 9 months 
after treatment due to progressive heart failure, while 
the others remain alive. Comparing the 6 months prior 
Table 3 SABR treatment details
Patient VTs targeted Planning target volume (mL) Beam on time (min) Linear accelerator Total time in room (min)
1 (STH) 1 65.8 7 Varian 60
2 (NUTH) 3 57.5 5 Varian 28
3 (JCUH) 2 139.0 12 Elekta 40
4 (NUTH) 1 121.1 5 Varian 35
5 (STH) 2 89.5 12 Varian 45
6 (NUTH) 2 101.5 5 Varian 33
7 (JCUH) 1 87.4 8 Elekta 30
JCUH, James Cook University Hospital Middlesbrough; NUTH, Newcastle Hospitals NHS Foundation Trust; SABR, stereotactic radiotherapy; 
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to treatment with 6 months after treatment we observed 
85% reduction in VT episodes—see figure 4, though 
in patient 4, the VT detection zones were suboptimally 
programmed prior to SABR treatment, and the number 
of episodes of VT prior to SABR was almost certainly 
undercounted. The majority of VT episodes were either 
non- sustained or terminated with antitachycardia pacing 
(ATP). Over the same time period, total ICD shocks 
across the whole group were reduced from seven pre- 
treatment to none post- treatment.
Following SABR, amiodarone dose was successfully 
reduced to 100 mg (n=2) or stopped (n=3), with the aim 
of reducing long- term toxicity and improving quality of 
life.
DISCUSSION
Our study shows effective (85%) VT suppression by 
cardiac SABR, applied on compassionate use basis, in a 
group of patients with heart failure and recurrent VT and 
few therapeutic options. Over the past decades, advances 
in medical therapy and cardiac resynchronisation have 
yielded improvements in heart failure survival with 
reduced sudden death.17 18 Successful VT management is 
also associated with improved survival,19 and reduction in 
VT episodes improves quality of life by less frequent ICD 
therapy, fewer hospital admissions and a reduction in 
AAD use.20 However, we accept that we did not formally 
measure quality of life in this series, and follow- up is 
limited to 6 months. We have chosen to report total 
VT episodes as the primary outcome to present the full 
‘biologic’ treatment effect; although ICD shock therapy 
may be considered a more clinically relevant endpoint, 
the total numbers of ICD shocks were small in this series.
Given the limited efficacy of second line AADs beyond 
amiodarone and significant challenges of catheter abla-
tion in frail patients,4 21 non- invasive SABR delivered on 
an outpatient basis could play an important role in VT 
management and symptom improvement. The extent 
of VT suppression seen in our cohort is in keeping with 
other series. Robinson et al reported ~90% suppression 
of VT in 19 patients,10 Neuwirth et al 87% in 10 patients 
out to median 28 months follow- up.9 Gianni et al on the 
other hand reported good initial effects of treatment in 
five patients followed for a median 12 months, but signif-
icant late recurrences of VT requiring re- escalation of 
AADs and repeat ablation in three patients.22 Lloyd et al 
reported 10 patients with more modest overall efficacy in 
terms of VT burden (69% reduction), ATP (48% reduc-
tion) and ICD shocks (68% reduction) in an advanced 
heart failure population.23
Figure 4 VT episodes in five patients that had at least 6 months follow- up comparing 6 months prior to SABR treatment (red) 
with 6 months post (blue). SABR, stereotactic radiotherapy; VT, ventricular tachycardia.
Figure 3 Panel A shows myocardium with some increase in capillary vascularity related to treatment, but minimal fibrosis, 
within tissue sampled from the targeted area. Panel B shows myocardial fibrosis close to but outside of the targeted area, 
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We emphasise that in this series SABR treatment was a 
‘last resort’ procedure for high- risk patients. Unsurpris-
ingly, we observed two acute and one mid- term deaths 
from non- arrhythmic causes in a cohort with advanced 
heart failure24—all three patients that died were NYHA 
class III or IV at SABR treatment. The Washington Univer-
sity group has recently reported that long- term survival 
of their 19 SABR- treated patients may be predicted by 
baseline cardiac function.25 Survivors (n=8, survival 
for median of 27.7 months) versus those who received 
cardiac transplant or died (n=11) had smaller cardiac 
volumes on echo and less myocardial scar on MRI. As 
SABR treatment places less demand on the patient, it is 
an attractive option for frail patients or those with more 
advanced heart failure, yet such patients may to be too 
sick to gain prognostic benefit. Nevertheless, given the 
ability of SABR to treat substrates inaccessible to cath-
eter ablation, it remains an attractive option for further 
investigation.
Cardiac SABR target selection is a challenge requiring 
integration and registration of imaging and functional 
data. In this series, and reflecting current worldwide 
experience and literature, we used a range of approaches 
from manual delineation methods to more sophisticated 
computer- assisted visualisation methods still under devel-
opment.26–28 The optimum dose and delivery platform 
for cardiac SABR is yet to be established. We used a single 
fraction 25 Gy regime as reported by all groups previously. 
While this did largely suppress VT (in one case at point 
of delivery), we also saw some short- term VT recurrences 
which may reflect incomplete substrate ablation. Like 
Robinson et al we employed gantry- based linear acceler-
ator systems, while Neuwirth et al and Gianni et al used 
the Cyberknife platform delivering radiotherapy via a 
robotic arm.10 22 Cyberknife treatment times are reported 
as longer—median 80 min versus 15 min, which could 
make consistent patient positioning and accurate delivery 
more challenging, although lower treatment volumes 
have been reported which might reduce off target effects.
At present, the mechanism(s) of action of cardiac 
SABR are not established. Alongside other reports, we 
observed acute VT suppression that seems too rapid to 
be explained by the development of radiation fibrosis. 
Our early postmortem data within weeks of SABR demon-
strated acute vascular changes but have not shown signif-
icant tissue injury or acute fibroblast proliferation, and 
this is consistent with the postmortem findings of little 
or no necrosis described by Cuculich et al and also Krug 
et al at similar time frames—3 weeks and 57 days post 
SABR, respectively.8 29 More recently, a four patient series 
ranging from 12 to 250 days post SABR treatment has 
reported both cardiac histology and electron microscopy 
findings of cellular necrosis and fibrosis.30 Our observa-
tion that troponin levels do not appear to rise acutely, 
although measured in only two patients, also makes early 
necrosis as observed in radiofrequency ablation unlikely. 
Preclinical studies do offer more scope to study radiobio-
logic effects. Studies in porcine and canine atrial models 
have confirmed scar formation at 4–6 months with high 
dose (>32 Gy) treatment.31 32 Rabbit and dog models have 
reported a paradoxical acute increase in cardiac conduc-
tion velocity following heavy ion irradiation, mediated 
through increased Connexin 43 expression.33 Data taken 
at serial timepoints up to 4 weeks post irradiation in 
a rat model did not show necrosis or apoptosis, rather 
interstitial and intracellular oedema, reflected in slowed 
conduction with prolongation of PR and QT intervals.34 
However, any perturbation of myocardial conduction 
whether increase or decrease may be sufficient to prevent 
re- entrant VT and most recent data again points to a 
‘supraphysiologic’ phenotype induced by radiation.35
The acute and late side effects of radiotherapy also 
need consideration, including those affecting the heart 
itself. We did not perform follow- up imaging apart from 
echo and did not document any clinically significant 
acute side effects, but long- term effects including peri-
cardial fibrosis and constriction, or coronary and valve 
disease are well- documented in cancer survivors and are 
a concern.36 There is increasing recognition that even at 
12–24 months, survival may be adversely affected in non- 
small cell lung cancer patients receiving higher dose off 
target treatment to the heart.37 Infrequent late effects of 
cardiac SABR treatment including pericarditis and gastric 
fistula have been reported as the follow- up of patients 
treated by this novel technique increases.38 Therefore, it 
is important to report all experience of this treatment, to 
help refine cardiac SABR techniques.
The unique features of this report are the collaborative 
approach to application of cardiac SABR across several 
centres within a larger health network (National Health 
Service), and the use of different planning and treatment 
delivery platforms. This report also presents the first use 
of a remote peer review system for cardiac SABR. SABR 
is a well- established oncology clinical service and the 
infrastructure is present in almost all NHS radiotherapy 
centres in the UK. There is also an established national 
multidisciplinary group (UK SABR Consortium) that 
provides expert consensus, quality assurance and liaison 
with clinical commissioners. The approach to cardiac 
SABR used so far is a direct translation from standard 
radiation oncology practice but further refinements will 
be possible, including improved or semiautomated three- 
dimensional target delineation, ECG or respiratory- gated 
treatment delivery, and optimisation of dosing and frac-
tionation regimes.
CONCLUSIONS
Our report confirms, in a UK multicentre setting, prior 
observations about the short- term and medium- term 
efficacy and safety of cardiac SABR for control of VT in 
a high- risk population that was refractory to standard 
approaches. There is still much to learn about this prom-
ising, novel non- invasive treatment and further research 
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